Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Fixed Dose Study to Assess Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bradanicline (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Therapeutic Use
- 12 Dec 2012 New source identified and integrated (Clinical Trials Registry - India: CTRI2009-091-001040).
- 13 Sep 2011 Primary endpoint 'Groton-Maze-Learning-Task' has been met.
- 03 Sep 2011 Results presented at the 24th Annual Congress of the European College of Neuropsychopharmacology.